Everest Medicines Announces Approval of Clinical Trial Application by China NMPA for Phase 3 Trial of Xerava(TM) for Community-Acquired Bacterial Pneumonia

Corporate Breaking News

Home : Everest Medicines Announces Approval of Clinical Trial Application by China NMPA for Phase 3 Trial of Xerava(TM) for Community-Acquired Bacterial Pneumonia

Aug 05 2021	Everest Medicines Announces Approval of Clinical Trial Application by China NMPA for Phase 3 Trial of Xerava(TM) for Community-Acquired Bacterial Pneumonia
SHANGHAI, Aug. 5, 2021 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Greater China and other parts of Asia, announced...


Source:https://www.prnewswire.com:443/news-releases/everest-medicines-announces-approval-of-clinical-trial-application-by-china-nmpa-for-phase-3-trial-of-xeravatm-for-community-acquired-bacterial-pneumonia-301348994.html

Related News
» Discovering Mysteries : lancement de la nouvelle saison du documentaire sur la nature de Hainan » Wallbox Closes First Half 2021 With Over 300% YOY Revenue Growth, Propelled By Global Expansion, Strategic Alliances And Growing Tailwinds